JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

Search

Crinetics Pharmaceuticals Inc

Open

BrancheGesundheitswesen

40.12 -1.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.79

Max

41.05

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-116M

Verkäufe

670K

1M

Gewinnspanne

-11,216.004

Angestellte

437

EBITDA

-19M

-129M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+99.36% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.4B

4B

Vorheriger Eröffnungskurs

41.16

Vorheriger Schlusskurs

40.12

Nachrichtenstimmung

By Acuity

50%

50%

168 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. Okt. 2025, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. Okt. 2025, 21:20 UTC

Ergebnisse

Correction to IBM 3Q Sales Jump Article

22. Okt. 2025, 20:57 UTC

Ergebnisse

SAP Posts Higher 3Q Revenue, Operating Profit

22. Okt. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Okt. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. Okt. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:15 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. Okt. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. Okt. 2025, 22:02 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. Okt. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. Okt. 2025, 21:58 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. Okt. 2025, 21:57 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. Okt. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. Okt. 2025, 21:47 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. Okt. 2025, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. Okt. 2025, 21:28 UTC

Market Talk
Ergebnisse

Correction to Alcoa Tariff Market Talk

22. Okt. 2025, 21:25 UTC

Ergebnisse

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. Okt. 2025, 21:17 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. Okt. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. Okt. 2025, 20:59 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 20:51 UTC

Ergebnisse

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Okt. 2025, 20:44 UTC

Ergebnisse

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer-Vergleich

Kursveränderung

Crinetics Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

99.36% Vorteil

12-Monats-Prognose

Durchschnitt 80.6 USD  99.36%

Hoch 143 USD

Tief 40 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Crinetics Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

15

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

30.39 / 33.46Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

168 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat